Erik Nordkamp – Managing Director, Pfizer UK
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Pfizer has a rich heritage of working within the UK since our first facility was opened back in 1952.
Over the past 69 years, we have continued to invest in the UK and are committed to working with the NHS and other healthcare organisations across the industry developing solutions to improve the delivery of care and patient outcomes.
We support the NHS Long Term Plan‘s ambition for prevention, empowering people to control their own health, harnessing new technologies and improving the quality of patient care and health outcomes. We believe these are key to help ensure a sustainable NHS and gives the government, the NHS and the pharmaceutical industry the chance to form a new relationship, truly working together to meet these challenges head-on while putting patients first.
In 2020, we spent over £295 million supporting research and development carried out in the UK and contributed to 126 collaborations with universities, pharmaceutical companies, industries and others. Through collaborations with scientists, academics and clinicians, sharing knowledge, skills and expertise we aim to improve the health and lives of people in the UK and around the world. During 2020, we had 36 clinical trials on-going in the UK, across 69 UK sites, involving over 977 patients since the trials started.
The company provides medicines to help treat a variety of serious and life–threatening conditions. With the combined portfolios and resources of Wyeth and Pfizer, Specialty Care has grown substantially. The business unit’s current portfolio includes more than 20 medicines in 12 disease areas, and the pipeline contains more than 25 compounds and indications in Phases II and III. Specialty Care holds leadership positions in vaccines and disease areas such as inflammation, infectious disease, hemophilia and ophthalmology. Neuroscience, Gastroenterology, Women’s Health, Infectious Diseases and Immunology.
Prescription medicines (top 50): Lipitor (1), Lyrica (15), Viagra (26), Xalatan (36).
Contact:
Headquarters: Walton Oaks, Dorking Rd, Tadworth KT20 7NS, Reino Unido
Tel: +44 (0)1304 616161, 0345 608 8866
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
Pfizer’s relationship with the North African Kingdom of Morocco dates back 57 years, and the US pharma giant is the only major multinational with a manufacturing presence in the country.…
Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more…
David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions.…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Patrick van der Loo oversees Pfizer’s operations across the vast Middle East, Russia and Africa (MERA) region. In a wide-ranging and insightful conversation, van der Loo outlines the company’s approach…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
See our Cookie Privacy Policy Here